Refine Your Results

Click below to filter your search results

"Gynecologic Cancers"Undo
"Medications or Drugs"Undo
"Guidelines"Undo

Search Results

Return to List
Results 1–4 of 4
Sort By: Relevance | Date | Title
1.

Aromatase Inhibitors in Gynecologic Practice

Number 663

(Replaces Committee Opinion Number 412, August 2008)

ABSTRACT Aromatase inhibitors have been used for the treatment of breast cancer ovulation induction endometriosis and other estrogenmodulated conditions For women with breast cancer bone mineral density screening is recommended with longterm aromatase inhibitor use because of risk of osteoporosis ...

June 2016

PDF Format
2.

The Use of Vaginal Estrogen in Women With a History of Estrogen-Dependent Breast Cancer

Number 659

ABSTRACT Cancer treatment should address femalespecific survivorship issues including the hypoestrogenicrelated adverse effects of cancer therapies or of natural menopause in survivors Systemic and vaginal estrogen are widely used for symptomatic relief of vasomotor symptoms sexual dysfunction and...

March 2016

PDF Format
3.

Options for Prevention and Management of Heavy Menstrual Bleeding in Adolescent Patients Undergoing

Number 606

ABSTRACT Adolescents undergoing cancer treatment are at high risk of heavy menstrual bleeding and gynecologists may be consulted either before the initiation of cancer treatment to request strategies for menstrual suppression or during an episode of severe heavy bleeding to stop the bleeding emerg...

August 2014

PDF Format
4.

Tamoxifen and Uterine Cancer

Number 601

(Replaces Committee Opinion Number 336, June 2006)

ABSTRACT Tamoxifen a nonsteroidal antiestrogen agent is widely used as adjunctive therapy for women with breast cancer and it has been approved by the US Food and Drug Administration for adjuvant treatment of breast cancer treatment of metastatic breast cancer and reduction in breast cancer incide...

June 2014

PDF Format

American Congress of Obstetricians and Gynecologists
409 12th Street SW, Washington, DC  20024-2188 | Mailing Address: PO Box 70620, Washington, DC 20024-9998